Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Obesity

A new paradigm for treating obesity and diabetes mellitus

Nature Reviews Endocrinology volume 11, pages 196–198 (2015)Cite this article

Subjects

An innovative strategy that uses a well-balanced monomeric peptide triagonist to target three metabolically related hormone receptors has been developed. This strategy seems to be the most effective pharmacological approach to reverse obesity and its metabolic comorbidities in rodents and could open new ways to tackle the dual burden of obesity and diabetes mellitus in humans.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Complementary (but also opposing) effects of the individual components of a peptide triagonist targeting GLP-1, GIP and glucagon receptors that could be used to treat obesity and type 2 diabetes mellitus.

References

  1. Scheen, A. J. & Van Gaal, L. F. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol. 2, 911–922 (2014).

    Article  CAS  Google Scholar 

  2. Finan, B. et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med. 21, 27–36 (2015).

    Article  CAS  Google Scholar 

  3. Sadry, S. A. & Drucker, D. J. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat. Rev. Endocrinol. 9, 425–433 (2013).

    Article  CAS  Google Scholar 

  4. Neumiller, J. J. Incretin-based therapies. Med. Clin. North Am. 99, 107–129 (2015).

    Article  Google Scholar 

  5. Campbell, J. E. & Drucker, D. J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17, 819–837 (2013).

    Article  CAS  Google Scholar 

  6. Unger, R. H. & Cherrington, A. D. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J. Clin. Invest. 122, 4–12 (2012).

    Article  CAS  Google Scholar 

  7. Lund, A., Bagger, J. I., Christensen, M., Knop, F. K. & Vilsbøll, T. Glucagon and type 2 diabetes: the return of the α cell. Curr. Diab. Rep. 14, 555 (2014).

    Article  Google Scholar 

  8. Arafat, A. M. et al. Glucagon regulates orexin A secretion in humans and rodents. Diabetologia 57, 2108–2116 (2014).

    Article  CAS  Google Scholar 

  9. Tan, T. M. et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 62, 1131–1138 (2013).

    Article  CAS  Google Scholar 

  10. Cegla, J. et al. Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes 63, 3711–3720 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Diabetes, Department of Medicine, Nutrition and Metabolic Disorders, CHU Liège, University of Liège, Liège, Belgium

    André J. Scheen & Nicolas Paquot

Authors
  1. André J. Scheen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicolas Paquot
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to André J. Scheen.

Ethics declarations

Competing interests

A.J.S. has received lecturer/advisor/investigator fees from AstraZeneca/BMS, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, NovoNordisk, Sanofi and Takeda. N.P. has received lecturer fees from Merck Sharp & Dohme and NovoNordisk.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Scheen, A., Paquot, N. A new paradigm for treating obesity and diabetes mellitus. Nat Rev Endocrinol 11, 196–198 (2015). https://doi.org/10.1038/nrendo.2015.3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2015.3

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing